Since last year, a sharp rise in demand for estrogen patches to manage menopause symptoms has pressured supply chains, leading to shortages that industry insiders warn could persist for as long as three years.
Each year, more than 1 million women in the U.S. enter menopause, and over the past two years, many have increasingly turned to these patches to help address symptoms such as mood changes, hot flashes and sleep issues. Social media has played a notable role in reshaping public perceptions around the safety and benefits of hormone therapies.
In July, the U.S. Food and Drug Administration publicly described hormone replacement therapy as lifesaving, and in November removed a long-standing safety warning tied to these treatments. Following this shift, usage of estrogen patches rose by over a quarter through February, based on data from Truveta.
A spokesperson for Swiss generics manufacturer Sandoz said that when the FDA lifted the safety warning in November, it triggered demand at a level that current supply cannot fully satisfy, noting that the company has sent additional product to the U.S. to help relieve shortages.
These patches deliver estrogen through the skin and into the bloodstream as part of hormone replacement therapy.
Gillian Goddard, assistant professor at the NYU Grossman School of Medicine, said that for two decades fewer than 5% of women used hormone therapy, but those figures are now rising. She added that increasing manufacturing capacity for these treatments is more complex than it may initially appear.
Although the U.S. Food and Drug Administration has not formally classified the products as being in shortage, many patients report visiting multiple pharmacies to find them. Some have adjusted dosages, switched brands or explored alternative therapies, according to interviews with patients, telehealth providers and industry sources.
Physicians caution that stopping treatment suddenly can cause symptoms to return, while changing products may introduce new side effects.
Amy Satterlund, a 50-year-old product manager based in Fort Pierce, Colorado, has relied on estrogen patches for roughly a year and a half but has recently encountered difficulty obtaining them. She explained that she now has to anticipate limited availability at CVS Health pharmacies and deal with delays when ordering through Cost Plus Drugs online. She said the possibility of missing refills worries her, as it could lead to the return of perimenopausal symptoms or other side effects.
A spokesperson for CVS Health noted that manufacturers have struggled to supply enough product in recent weeks. Meanwhile, a representative for Cost Plus Drugs said the company has increased inventory to meet surging demand but has not received indications from suppliers that shortages will persist long term.
Andrew Nixon, a spokesperson for the U.S. Department of Health and Human Services, said the agency is working alongside manufacturers to help expand production and improve availability of the patches.
In interviews and public statements, FDA Commissioner Marty Makary explained that earlier concerns, particularly around cancer risk, had led to widespread hesitation among women but the evolving scientific evidence has since prompted a reassessment of those risks.
What Is Driving the Estrogen Shortage?
Several factors are contributing to the current Estrogen shortage, including manufacturing delays, supply chain disruptions, and increased demand. Pharmaceutical companies producing Estrogen medications have reported difficulties in maintaining consistent production levels, further tightening availability.
Additionally, regulatory hurdles and quality control issues have slowed down distribution, making it harder for pharmacies to keep Estrogen products in stock.
Impact on Patients and Healthcare Providers
The Estrogen shortage is particularly concerning for patients undergoing hormone replacement therapy, as well as those receiving treatment for conditions such as menopause-related symptoms and certain cancers. Interruptions in Estrogen therapy can lead to:
- Return of severe symptoms
- Hormonal imbalances
- Increased health risks over time
Healthcare providers are now facing the challenge of managing treatment plans without reliable access to Estrogen, often needing to adjust prescriptions or explore less optimal alternatives.
